Loss-of-Function Variants Associated with Gastric Cancer Risk
the Cancer Therapy Advisor take:
Loss-of-function mutations in ATM were associated with an increased risk for developing gastric cancer, according to an article published online in the journal Nature Genetics.
A Genome-wide association study (GWAS) in a European population with information on 2,500 cases of gastric cancer and 205,652 controls was reported.
The authors found a new association between gastric cancer and the loss-of-function mutations in ATM gene test, P = 8.0 × 10−12; OR = 4.74). Patients carrying the loss-of-function mutations were diagnosed with cancer significantly earlier in age than those not carrying the variations.
Furthermore, a combination of the loss-of-function mutations p.Gln852, p.Ser644, and p.Tyr103 (combined minor allele frequency (MAF) = 0.3%) were linked with pancreatic (OR = 3.81) and prostate (OR = 2.18) cancer and indicated a risk of breast (OR = 1.82) and colorectal (OR = 1.97) cancer.
Results confirmed a relationship between the three loci associated with gastric cancer in Asia (MUC1, PRKAA1 and PSCA) and gastric cancer in Europeans.
Loss-of-function mutations in ATM were associated with an increased risk for developing gastric cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Calcium and Cancer
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective
- Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer
- Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse
- Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection
- Outcomes in Pancreatic Cancer Not Improved by Gemcitabine Plus Erlotinib
- Cabozantinib Effective as Salvage Therapy in Thyroid Cancer
- Q&A With Kristian Thidemann Andersen, MD, PhD: Infection in Multiple Myeloma After HDT-ASCT